We confirmed that EBNA2 was a negative regulator of CD79A and CD79B in both LCL and lymphoma cell backgrounds and we also showed reduced CD79A and CD79B protein levels in response to EBNA2 activation in LCLs. This evidence concerns the gene CD79A and lymphoma.